Energy & Endurance

MOTS-c

Evidence

What is MOTS-c?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a naturally occurring peptide made of 16 amino acids. Most peptides are encoded by DNA in the cell nucleus; MOTS-c comes from mitochondrial DNA, specifically a small region inside the mitochondrial 12S rRNA gene. The FDA's 2026 scientific review also describes it as a naturally occurring mitochondrial peptide of 16 amino acids.

MOTS-c appears to be involved in how cells respond to energy demand, metabolic stress, glucose availability, exercise and changes in mitochondrial function. Most of what is known about its possible treatment effects comes from cell and animal research rather than completed human injection trials.

MOTS-c is peptide-based, encoded by mitochondrial DNA and involved in metabolic signaling. It is not a stimulant, a GLP-1 agonist, insulin, growth hormone, or a conventional drug with one clearly identified receptor.

How well studied is it?

The science is interesting, but injected-human research is only beginning. MOTS-c has strong laboratory research, many animal studies, human studies measuring the MOTS-c the body naturally produces, human exercise research, and an active Phase 2a human treatment trial.

There are not yet published results from controlled trials showing that injected native MOTS-c improves insulin sensitivity, body weight, body composition, energy, endurance or exercise performance in humans. The FDA's 2026 review found no published studies in which MOTS-c had been given to humans that could establish its safety or effectiveness, and described human safety and effectiveness as unknown. A Phase 2a study is now testing MOTS-c in adults with prediabetes and overweight or obesity.

Evidence level

Overall evidence rating: strong preclinical science, very early injected-human evidence

• Strong evidence for: MOTS-c exists naturally, its 16-amino-acid structure, its mitochondrial DNA origin, its involvement in metabolic signaling, natural MOTS-c changing with exercise, and metabolic effects in animal and cell models.
• Currently being tested in humans: insulin sensitivity, glucose-related markers, body weight, waist circumference, and the safety of repeated SC treatment.
• Not established in injected humans: fat loss, endurance, energy improvement, GLP-1 fatigue relief, anti-aging, longevity, best dose, best frequency, best timing, injection half-life, need for cycling, and true adverse-effect rates.

Primary research focus

• Current human trial focus: insulin sensitivity, prediabetes, overweight / obesity, metabolic health.
• Animal / cell research focus: glucose metabolism, metabolic flexibility, skeletal-muscle metabolism, obesity, physical capacity, aging-related metabolic changes.
• Not established: bodybuilding, athletic enhancement, fat-loss treatment, fatigue treatment, longevity treatment, anti-aging treatment.

What may it help with?

Currently being tested in humans: insulin sensitivity. The Phase 2a MOTS-MET trial is studying adults with prediabetes, overweight or obesity, and insulin resistance. The main question is whether about 12 weeks of MOTS-c treatment can improve insulin sensitivity compared with placebo. The trial has not reported results yet: MOTS-c is being studied for insulin sensitivity in humans, and it has not been shown to improve it.

Human exercise research. The MOTS-c naturally produced by the body changes with exercise. A 2021 study found that exercise increased endogenous MOTS-c in human skeletal muscle and circulation, and human observational studies have found relationships between MOTS-c and metabolic characteristics. This suggests MOTS-c is part of the body's normal response to exercise and increased energy demand. It does not show that injecting MOTS-c recreates exercise, improves endurance, causes fat loss, improves blood sugar or increases mitochondrial function in humans.

Animal and cell evidence. Animal and laboratory studies suggest MOTS-c may affect insulin sensitivity, glucose metabolism, metabolic flexibility, obesity-related metabolism, physical capacity, skeletal-muscle function and age-related metabolic changes. These findings are why MOTS-c is now being tested in humans, but they remain animal or laboratory effects until human treatment results are available.

What has it not been proven to help with?

Injected MOTS-c has not been proven in humans to:

• cause fat loss or treat obesity
• reverse insulin resistance or treat diabetes
• improve endurance or athletic performance
• improve mitochondrial function or build new mitochondria
• increase energy or treat fatigue, including GLP-1-related fatigue
• build muscle, prevent muscle loss or speed recovery
• extend lifespan or reverse aging
• improve metabolic flexibility or body composition
• increase human fat burning after injection, or replace exercise

These effects are not impossible; there are no controlled human injection results showing them yet.

Dosing evidence

Human clinical research: Phase 2a MOTS-MET trial

This is an investigational research regimen, not an approved MOTS-c treatment protocol.

FDA compounding nomination doses

Products submitted in the FDA compounding nomination included 5 mg and 10 mg for SC injection. The FDA describes these as proposed compounded products, not approved or validated doses. A dose being nominated to the FDA does not mean the FDA approved it; the FDA's 2026 scientific review concluded that the evidence weighed against placing MOTS-c free base or MOTS-c acetate on the 503A Bulks List.

Research-community dosing

Community protocols are very different from the clinical trial. PeptideFox describes approximately:

• Dose: 5–10 mg per injection, with 5 mg a commonly discussed starting amount
• Route: SC or IM
• Frequency: commonly 2–3 times per week
• Timing: often in the morning or around exercise
• Cycle: commonly 4–6 weeks followed by a break

Other community protocol examples include 5 mg weekly followed by twice weekly, 10 mg weekly, 200 mcg increasing to 1 mg daily, 5 mg every 5 days, and 3 mg every 3 days. No human dose-ranging study shows that any one of these is a standard MOTS-c protocol. These doses have not been established by completed human dose-finding trials of native MOTS-c.

Evidence check for community protocols

Protocol comparison

SC is currently the route with the strongest human-research precedent. Dose and frequency are the biggest unknowns: there are no completed human data establishing the best regimen.

Frequency

The Phase 2a trial uses repeated SC treatment across 12 weeks, which will provide important information about repeated human exposure. Community protocols commonly use 2–3 times per week; other community schedules include once weekly, every few days, and higher-frequency short cycles. No completed human trial has established the best dosing frequency.

Timing

There is no established human evidence that injected MOTS-c needs to be taken before or after exercise, in the morning or at night, fasted or with food. Pre-workout is not a required dosing window.

Community protocols often use MOTS-c in the morning, before cardio or before endurance training, and PeptideFox describes pre-exercise timing. The idea is understandable because the body's own MOTS-c increases during exercise, but that does not show an injection works better before exercise.

Duration and cycling

The Phase 2a study uses 12 weeks of treatment followed by additional safety follow-up. Community protocols often use about 4–6 weeks on followed by 2–4 weeks off. The trial duration is simply how the trial was designed, and the community cycle is a community convention; neither shows that MOTS-c biologically requires cycling.

Whether MOTS-c needs to be cycled is unknown. There is no human evidence that it requires a break to reset a receptor, restore sensitivity or prevent tolerance. A specific MOTS-c receptor has not been clearly identified; the FDA's 2026 review states that its molecular target or targets remain unknown.

Expected results timeline

Clinical research: no injected-human results timeline yet

The first Phase 2a study is still underway. There are no published results from controlled MOTS-c injections in humans showing that insulin sensitivity improves by week 2, fat loss starts at week 4, endurance improves at week 6, or energy increases within days.

The trial is looking at metabolic outcomes after approximately 12 weeks of treatment, with safety monitoring continuing afterward. The main focus is insulin sensitivity; other measurements include blood-sugar and cardiometabolic markers.

Exercise can change the MOTS-c naturally present in the body. That says something about MOTS-c biology, but not how quickly an injection produces a treatment effect.

Commonly reported community timeline

Community material describes subjective changes in energy or exercise tolerance over roughly several days to several weeks, often discussed during 4–6 week community cycles. These reports are anecdotal and have not been confirmed in controlled human MOTS-c injection trials.

Protocol logic check

Does daily dosing make sense?

Repeated SC treatment is now being tested in the Phase 2a trial, which makes the trial more relevant than older community schedules. The trial has no results yet.

Does 2–3 times weekly or once-weekly dosing make sense?

Two to three times weekly is common in peptide communities, but no completed human study shows it is the best schedule. Some community protocols use once-weekly injections; there is no human research showing that one injection per week provides enough exposure for the proposed metabolic effects.

Does pre-workout timing make sense?

Natural MOTS-c increases during human exercise, so pairing an experimental injection with exercise may sound logical. No human trial has shown that injections work better 30, 60 or 90 minutes before exercise than at another time, and no evidence says MOTS-c has to be used with exercise.

Fasted, morning or evening dosing

Fasting activates many energy-sensing pathways, which gives fasted use some biological logic, but no human injection study has shown MOTS-c works better while fasted. Whether morning or evening is better is unknown; morning use is mostly a community preference, often because users combine MOTS-c with exercise.

4–6 weeks on / 2–4 weeks off, receptor resets and washouts

No human research shows that MOTS-c stops working after 4–6 weeks, or that several weeks off restores sensitivity. Because there is no clearly identified MOTS-c receptor, claims that "the MOTS-c receptor needs to reset" are especially weak. No 2-week break, 4-week break or reset period has been established.

Dose escalation / titration

Community protocols range from 200 mcg increasing to 1,000 mcg daily to schedules using 3 mg, 5 mg or 10 mg at different intervals. There is no completed human dose-ranging study showing that any of these ladders is correct; they are separate community protocols, not clinical titration schedules.

Does the route match the research?

The current human trial and the FDA compounding nomination both use SC; community use is SC or IM. SC has the strongest human-research precedent, which means SC is being studied, not that SC efficacy has been proven.

Mechanism and pharmacokinetics

What does MOTS-c target?

MOTS-c does not have one clearly identified receptor the way liraglutide acts on the GLP-1 receptor or tesamorelin on the GHRH receptor. Laboratory research suggests it affects several parts of cellular metabolism, including folate metabolism, purine metabolism, AICAR, AMPK-related signaling and stress-response genes. Under metabolic stress, MOTS-c can also move into the nucleus and affect gene activity.

Simplified pathway: folate metabolism, then AICAR, then AMPK-related signaling.

MOTS-c appears to help cells respond to metabolic stress and changing energy demands, and AMPK seems to be part of that response. AMPK is not an identified MOTS-c receptor, and MOTS-c does not bind an "AMPK receptor". The FDA's 2026 review states that the molecular target or targets through which MOTS-c works remain unknown.

Human half-life

Unknown. There is no established published half-life for native injected MOTS-c in humans, so there is no basis for claims that it lasts a certain number of hours, needs redosing on that basis, or that one dose provides a set number of days of signaling.

How long do the effects last?

Also unknown in injected humans. A short period of peptide exposure could possibly trigger longer-lasting metabolic changes, but this has not been measured well enough in humans to give a reliable duration.

Does it build up with repeated use?

Unknown. There are no published human injection data showing how much MOTS-c builds up, whether it reaches steady levels, how quickly it washes out, or how long it stays in tissues.

What studies have found

Foundational MOTS-c research

Foundational research identified MOTS-c as a mitochondrial-derived peptide involved in metabolic regulation. Animal and laboratory work found effects involving metabolic homeostasis, insulin resistance and obesity-related metabolism. This supports MOTS-c being biologically active, real metabolic signaling and plausible AMPK-related mechanisms. It does not support a human 5 mg protocol, human fat loss, human endurance enhancement or human anti-aging therapy.

Human exercise research

Human research shows that natural MOTS-c increases with exercise, and acute endurance exercise changes circulating mitochondrial-derived peptides. MOTS-c appears to take part in normal human exercise biology. This does not establish an injection protocol timed 30, 60 or 90 minutes before exercise.

MOTS-MET Phase 2a trial

The trial (NCT07505745) is studying about 120 adults with prediabetes and overweight or obesity, comparing MOTS-c with placebo over approximately 12 weeks with further safety follow-up. The main question is whether MOTS-c can improve insulin sensitivity. Status: ongoing. Results: not available yet.

FDA 2026 evaluation

The FDA reported that its literature search did not identify human administration studies that could establish MOTS-c's effectiveness or safety, and noted that its exact molecular targets remain unknown. Human insulin-sensitivity improvement, endurance improvement, hypoglycemia as a major known side effect, a known human half-life, standard 5 mg dosing and mandatory pre-workout use are therefore not established facts.

Four types of MOTS-c evidence that are often mixed together

• Natural human MOTS-c: humans produce MOTS-c, and exercise studies show natural levels change with physical activity. This is real human evidence, but not evidence from injections.
• Animal and cell research: the source of many claims, covering insulin sensitivity, glucose metabolism, obesity, endurance, physical function and aging-related changes. Mouse results are not human treatment results.
• Current human Phase 2a research: about 120 adults with prediabetes and overweight or obesity, MOTS-c against placebo for about 12 weeks. Ongoing, with no published efficacy results yet.
• Community injection protocols: 5 mg, 10 mg, multiple injections per week, pre-workout timing, cycling and stacking. These are community protocols, not human clinical dosing.

Storage

No FDA-approved MOTS-c product exists

There is no approved reference product giving one universal vial strength, mixing method, diluent, storage temperature after mixing, or expiration after reconstitution.

Product quality concerns

The FDA identified concerns involving impurities, peptide aggregation, immune reactions, product identity, bacterial endotoxins, and differences between free-base and acetate products. The FDA considers MOTS-c free base and MOTS-c acetate to be different bulk drug substances and identified significant characterization concerns with both. Not every vial labeled "MOTS-c" can be assumed to contain the same pharmaceutical substance.

Community research vials

Community sources give their own instructions for bacteriostatic water, refrigeration and use-after-mixing periods. These are community handling practices, not validated MOTS-c stability data. No single 14-day, 28-day or 30-day storage rule applies to every MOTS-c vial; storage and handling depend on evidence for the exact formulation.

Contraindications

Formal contraindications

None established. MOTS-c is not an FDA-approved medication, so there is no approved product label with an official contraindication list. Theoretical concerns are not formal contraindications.

Important cautions

• Pregnancy: no human fetal-safety information exists. Safety unknown; experimental exposure is best avoided.
• Breastfeeding: no adequate human safety data.
• Children and adolescents: no established injected-MOTS-c safety or effectiveness. Unstudied.
• Diabetes medications: because MOTS-c is being studied for insulin sensitivity, combining it with insulin, sulfonylureas or other glucose-lowering drugs could potentially change glucose control. No human interaction study shows the size of that risk. An important theoretical caution, not a proven contraindication.
• Metformin: MOTS-c and metformin research involve some of the same signaling pathways, including AMPK-related biology. This does not show the combination is dangerous; the actual interaction is unknown.
• Active cancer: not enough human data to establish safety in people with active malignancy. Unknown risk, not a formal contraindication.
• Serious cardiovascular disease: human injection safety is not established.
• Immune reactions: the FDA specifically identified immunogenicity as a concern with injectable compounded MOTS-c products.

Side effects

Human safety profile: not established

There is no completed human injection study of native MOTS-c that gives reliable data on common, uncommon or serious side effects, or their rates. The FDA's 2026 review said there was not enough human administration information to determine the safety of MOTS-c.

FDA safety concerns

The FDA highlighted possible concerns involving immune reactions to the peptide, peptide clumping or aggregation, impurities, differences between products sold as MOTS-c, manufacturing consistency, and inadequate characterization of the active ingredient. These concerns are particularly important for injected peptide products.

Community-reported or theoretical effects

Community material describes injection-site irritation (redness, soreness, irritation), fatigue, temporary discomfort and occasional stomach symptoms. Other effects sometimes listed, such as hypoglycemia, flushing, GI symptoms, headache, flu-like symptoms or "AMPK overstimulation", are community-reported or theoretical. Their frequency in humans is not known, and none is an established clinical adverse-effect rate.

Hypoglycemia

MOTS-c is being studied because it may affect insulin sensitivity and glucose metabolism, so changes in glucose control are biologically worth watching. Low blood sugar has not been established as the main adverse effect of injected MOTS-c in humans: it is possible in theory but unconfirmed, and there is no evidence that MOTS-c must always be used before exercise to prevent it.

Regulatory status

Compatibility

Stack / pairing logic

Sources

1. Lee et al. 2015. The mitochondrial-derived peptide MOTS-c (foundational preclinical research): 16-amino-acid mitochondrial-derived peptide, mitochondrial DNA origin, metabolic signaling, animal insulin-resistance and obesity findings, AMPK-related pathway. pubmed.ncbi.nlm.nih.gov/25738459
2. Reynolds et al. 2021. MOTS-c and exercise. Human physiological and animal experimental research: exercise-related endogenous MOTS-c changes in human muscle and circulation, animal physical-capacity research; does not establish injected-human efficacy. pubmed.ncbi.nlm.nih.gov/33473109
3. von Walden et al. 2021. Acute endurance exercise and circulating mitochondrial-derived peptides. Human physiological research; does not establish a pre-workout injection protocol. pubmed.ncbi.nlm.nih.gov/34351816
4. ClinicalTrials.gov. MOTS-MET Phase 2a (NCT07505745). Active human clinical trial: adults with prediabetes and overweight/obesity, SC administration, 12-week treatment, insulin-sensitivity outcome, safety monitoring. clinicaltrials.gov/study/NCT07505745
5. U.S. FDA. 2026 evaluation of MOTS-c for the 503A Bulks List. Scientific and regulatory review: no FDA-approved MOTS-c drug, no established human administration evidence, unknown human safety, insufficient effectiveness evidence, immunogenicity and free-base vs acetate concerns, staff conclusion against 503A inclusion. fda.gov
6. U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks. Immunogenicity, peptide impurity and active-ingredient characterization concerns; lack of adequate human safety information. fda.gov
7. U.S. FDA. July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. Review of MOTS-c free base and acetate. fda.gov
8. World Anti-Doping Agency. 2026 Prohibited List. MOTS-c listed as an AMPK activator; prohibited under WADA rules. wada-ama.org
9. PeptideFox. MOTS-c. Community / practitioner protocol: community dosing, multiple weekly injections, SC / IM use, exercise timing, cycling, anecdotal timelines and handling practices. peptidefox.com